The facility expands Matica Bio’s capabilities as a CDMO, with the company emphasizing its ability to meet the biopharmaceutical industry’s need for faster delivery of cells and viral vectors that are important components of some of the most promising novel therapies.
“The key is faster delivery without sacrificing quality or safety,” said Matica Bio CEO Yun Jeong Song.
“Our new facility is designed for rapid development, scale-up and production for clinical supply, but our experienced teams provide quality oversight and regulatory guidance necessary to ensure success. Solely committed to our clients’ commercialization goals, we have the expertise and an advanced, modular system that provides the flexibility to adjust resources required depending on client need and product requirements.”
Research collaborations
Helping meet the need for speed, the Texas CDMO has already established two collaborations at the new facility.
Firstly, the company is working with Sartorius to develop and optimize advanced viral vector manufacturing technologies for large-scale vector production.
Secondly, it has partnered with Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech R&D and commercial manufacturing.
“We’re aiming to improve multiple components across the cell and gene therapy production process, including ease of manufacturability, real-time data read-outs, reducing costs and solving anticipated challenges of large-scale cell culture and viral vector production,” said Matica Bio chief technology officer Mike Stewart. “These collaborations are just the start of Matica Bio’s commitment for future expansion of research, expertise and successful product development.”
